RU2012122700A - Структура сокристалла фактора d и антитела к фактору d - Google Patents

Структура сокристалла фактора d и антитела к фактору d Download PDF

Info

Publication number
RU2012122700A
RU2012122700A RU2012122700/10A RU2012122700A RU2012122700A RU 2012122700 A RU2012122700 A RU 2012122700A RU 2012122700/10 A RU2012122700/10 A RU 2012122700/10A RU 2012122700 A RU2012122700 A RU 2012122700A RU 2012122700 A RU2012122700 A RU 2012122700A
Authority
RU
Russia
Prior art keywords
factor
polypeptide
antibody
crystal
seq
Prior art date
Application number
RU2012122700/10A
Other languages
English (en)
Russian (ru)
Inventor
Менно Ван Локерен КАМПАГНЕ
Кристиан ВИСМАНН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2012122700A publication Critical patent/RU2012122700A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2012122700/10A 2009-11-04 2010-11-04 Структура сокристалла фактора d и антитела к фактору d RU2012122700A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US61/280,460 2009-11-04
US28171609P 2009-11-20 2009-11-20
US61/281,716 2009-11-20
PCT/US2010/055509 WO2011057014A1 (en) 2009-11-04 2010-11-04 Co-crystal structure of factor d and anti-factor d antibody

Publications (1)

Publication Number Publication Date
RU2012122700A true RU2012122700A (ru) 2013-12-10

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012122700/10A RU2012122700A (ru) 2009-11-04 2010-11-04 Структура сокристалла фактора d и антитела к фактору d

Country Status (14)

Country Link
US (1) US20110165648A1 (enExample)
EP (1) EP2496695A1 (enExample)
JP (1) JP2013509866A (enExample)
KR (1) KR20120120153A (enExample)
CN (1) CN102666850A (enExample)
AR (1) AR078886A1 (enExample)
BR (1) BR112012011607A2 (enExample)
CA (1) CA2782481A1 (enExample)
IN (1) IN2012DN03338A (enExample)
MX (1) MX2012005430A (enExample)
RU (1) RU2012122700A (enExample)
TW (1) TW201121993A (enExample)
WO (1) WO2011057014A1 (enExample)
ZA (1) ZA201202602B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
MX2018005226A (es) * 2015-10-30 2019-04-29 Genentech Inc Formulaciones de anticuerpo anti-factor d.
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018250695A1 (en) 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
ZA201202602B (en) 2013-06-26
CN102666850A (zh) 2012-09-12
US20110165648A1 (en) 2011-07-07
AR078886A1 (es) 2011-12-07
IN2012DN03338A (enExample) 2015-10-23
TW201121993A (en) 2011-07-01
MX2012005430A (es) 2012-06-19
JP2013509866A (ja) 2013-03-21
BR112012011607A2 (pt) 2020-06-02
KR20120120153A (ko) 2012-11-01
WO2011057014A1 (en) 2011-05-12
EP2496695A1 (en) 2012-09-12
CA2782481A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
AR078886A1 (es) Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades
RU2491293C2 (ru) Иммунологические анализы активности ботулинического токсина серотипа а
Blech et al. One target—two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β
RU2013136908A (ru) Антитела kil-12/il-23 и их применение
JP2014524733A5 (enExample)
JP2010514805A5 (enExample)
JP7603023B2 (ja) 心不全を評価するためのアッセイ
US20160061844A1 (en) PIIINP Neo-epitope Assay
CN113892031B (zh) 混合检测PCT和Presepsin的试剂盒、方法以及应用
EP4157867A1 (en) Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein
CN102887943A (zh) 氨基末端脑钠肽的b细胞表位肽段及其应用
Lévêque et al. Direct biosensor detection of botulinum neurotoxin endopeptidase activity in sera from patients with type A botulism
Robinson et al. Lower extremity bypass and endovascular intervention for critical limb ischemia fail to meet Society for Vascular Surgery's objective performance goals for limb-related outcomes in a contemporary national cohort
AU2009287086B2 (en) Method to screen high affinity antibody
WO2017134172A1 (en) Combined biomarker measurement of fibrosis
KR20180102647A (ko) 콜라겐 타입 vii 알파 1 분석
WO2019129679A1 (en) Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
CN108700570B (zh) 交联纤维蛋白分解产物的测定试剂及测定方法
Baessler et al. Adiponectin multimeric forms but not total adiponectin levels are associated with myocardial infarction in non-diabetic men
RU2018109920A (ru) Специфически очищенные антитела против пресепсина
Hoshi et al. Surface X-ray scattering of high index plane of platinum containing kink atoms in solid–liquid interface: Pt (3 1 0)= 3 (1 0 0)–(1 1 0)
KR102025446B1 (ko) 프로필라그린 c 말단 도메인 특이적 항체 및 그의 용도
Bhandari et al. The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension
EP4255928A1 (en) Il-7 binding proteins and their use in medical therapy
Ajjan et al. Thyroid autoantibodies

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20131105